Colorectal cancer prevention and treatment.

[1]  E. Lamont,et al.  The oral fluoropyrimidines in cancer chemotherapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Feldman,et al.  Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. , 1999, Gastroenterology.

[3]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[4]  F. Lévi,et al.  Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  H. Iishi,et al.  Inhibition of angiogenesis as a mechanism for inhibition by Lα‐hydroxyvitamin D3 and 1,25‐dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats , 1999, International journal of cancer.

[6]  C. Erlichman.  Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Rockette,et al.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  V. Steele,et al.  Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. , 1999, Cancer research.

[9]  M. Buyse,et al.  Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Love,et al.  A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  C. Tournigand,et al.  Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[13]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[14]  F. Speizer,et al.  Multivitamin Use, Folate, and Colon Cancer in Women in the Nurses' Health Study , 1998, Annals of Internal Medicine.

[15]  J. Rüschoff,et al.  Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Schilsky,et al.  Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Ajani,et al.  Uracil-tegafur in gastric carcinoma: a comprehensive review. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Ychou,et al.  Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Fitzgibbons,et al.  Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[21]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[22]  L. Marnett,et al.  Aspirin-like molecules that covalently inactivate cyclooxygenase-2. , 1998, Science.

[23]  J. Manson,et al.  Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study , 1998, Annals of Internal Medicine.

[24]  C. J. Barnes,et al.  Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. , 1998, Gastroenterology.

[25]  R. Schilsky,et al.  Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. de Gramont,et al.  Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. , 1998, Seminars in oncology.

[27]  V. Steele,et al.  Effect of Tea Extracts, Polyphenols, and Epigallocatechin Gallate on Azoxymethane-induced Colon Cancer , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[28]  R. Pazdur,et al.  Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. , 1998, Cancer investigation.

[29]  M. Kahn,et al.  Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Bertagnolli,et al.  The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. , 1998, Carcinogenesis.

[31]  M. Buyse,et al.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[33]  D. Leipold,et al.  R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. , 1997, Cancer research.

[34]  M. Ducreux,et al.  5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. , 1997, European journal of cancer.

[35]  C. Rock,et al.  Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. , 1997, Journal of the National Cancer Institute.

[36]  J. Morrow,et al.  Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.

[37]  A. Hara,et al.  Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. , 1997, Carcinogenesis.

[38]  L Påhlman,et al.  Improved survival with preoperative radiotherapy in resectable rectal cancer. , 1997, The New England journal of medicine.

[39]  C. Rao,et al.  Chemoprevention of colon cancer by organoselenium compounds and impact of high- or low-fat diets. , 1997, Journal of the National Cancer Institute.

[40]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Thun.  Aspirin and gastrointestinal cancer. , 1997, Advances in experimental medicine and biology.

[42]  Z. Cohen,et al.  Sulindac for periampullary polyps in FAP patients , 1997, International Journal of Colorectal Disease.

[43]  L. Grochow,et al.  Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. DuBois,et al.  Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. , 1996, Gastroenterology clinics of North America.

[45]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[46]  J. Mason,et al.  Dietary folate protects against the development of macroscopic colonic neoplasia in a dose responsive manner in rats. , 1996, Gut.

[47]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[48]  G. Kelloff,et al.  Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. , 1996, Cancer research.

[49]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Tadataka Yamada,et al.  Textbook of Gastroenterology , 1995 .

[51]  T. Fleming,et al.  Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Cats,et al.  Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. , 1995, Journal of the National Cancer Institute.

[53]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[54]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[55]  J. Ajani,et al.  Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  A. Bhattacharyya,et al.  Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. , 1994, Cancer research.

[57]  Y. Niv,et al.  Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. , 1994, Gastroenterology.

[58]  H. Wieand,et al.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. , 1994, The New England journal of medicine.

[59]  C. Moertel.  Chemotherapy for colorectal cancer. , 1994, The New England journal of medicine.

[60]  P. Dolara,et al.  Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. , 1994, Gastroenterology.

[61]  H. Wieand,et al.  Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[63]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  W. Meyers,et al.  Effective surgical adjuvant therapy for high-risk rectal carcinoma. , 1991, The New England journal of medicine.

[66]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[67]  R. Elston,et al.  Hereditary nonpolyposis colorectal cancer (lynch syndromes I and II). I. Clinical description of resource , 1985, Cancer.

[68]  K. Ikenaka,et al.  Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. , 1979, Gan.